$2.49
-0.03 (-1.19%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LTRN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 4 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MARSHALL WACE, LLP) · FINRA short interest 10.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid TumorsNCT06132503Phase 1a: To evaluate the safety and tolerability of escalating doses of LP-284Open-label · Treatment | Phase 1 | Recruiting | Drug: LP-284 | Relapsed or Refractory Lymphomas, Advanced Solid Tumor | 110 | 2028-11-30 | in 833 d | 2026-05-04 |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaNCT05456256Progression-free survival (PFS)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: LP-300, Pemetrexed, Carboplatin | Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung | 90 | Dec 2026 | ≤ 133 d | 2026-05-04 |
| Study of LP-184 in Patients With Advanced Solid TumorsNCT05933265To evaluate the safety and tolerability of LP-184 assessed by the incidence and severity of all adverse events graded by CTCAE v5.0Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: LP-184, Olaparib, Nivolumab & Ipilimumab | Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation | 64 | 2026-07-28 | — | 2026-05-04 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19